Knowledge on rare diseases worldwide
Orphanet (orpha.net) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Non-profit brands, Education brands, in the 48th percentile of 13219 Healthcare brands.
Orphanet is a non-profit organization founded in 1997 that provides a comprehensive, freely accessible database on rare diseases and orphan drugs. It consolidates fragmented medical knowledge into a single, trusted encyclopaedia, also listing related genes and a directory of patient organisations. Orphanet serves healthcare professionals, researchers, patients, families, and advocacy groups seeking reliable, high-quality information to improve diagnosis, care, and treatment of rare diseases worldwide.
| Brand Name | Orphanet |
|---|---|
| Domain | orpha.net |
| Industry | Healthcare, Non-profit |
| Founded | 1997 |
| Main Competitors | National Organization for Rare Disorders (NORD) (86/100), Genetic and Rare Diseases Information Center (GARD), Online Mendelian Inheritance in Man (OMIM) (71/100), MalaCards |
Moz Domain Authority 68/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #25,964 on the Tranco list of most-visited sites - strong traffic reinforces the brand's prominence to AI models.
Orphanet has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "To improve the diagnosis, care, and treatment of patients with rare diseases by providing comprehensive, high-quality information on rare diseases and orphan drugs." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:image, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, YouTube, X (Twitter), Instagram; no detected presence on Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Orphanet?", Claude could identify the brand as of October 2026. Orphanet is a reference portal and database for rare diseases and orphan drugs, originally established by France's INSERM and now supported by a consortium of countries. It provides information on rare disease nomenclature, classification, clinical features, and expert centers to Best known for being the leading international database and classification system for rare diseases.
When asked "Best brands similar to Orphanet?", Claude would recommend Orphanet as of October 2026. It's the go-to reference for rare disease information and nomenclature, widely used by clinicians, researchers, and patient organizations worldwide.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Orphanet's main competitors in Healthcare: National Organization for Rare Disorders (NORD) (86/100), Online Mendelian Inheritance in Man (OMIM) (71/100).
Sources: Brand Analyzer scan
Orphanet offers a free, comprehensive inventory and encyclopaedia of rare diseases and orphan drugs, along with information on related genes. It also provides a directory of patient organisations, enabling patients and families to find relevant advocacy and support groups. These resources are designed to support diagnosis, care, and treatment decisions for rare disease patients.
Sources: Orphanet official site
Orphanet is a non-profit organization, founded in 1997, that maintains a comprehensive database and encyclopaedia on rare diseases and orphan drugs. It serves as a global reference resource, consolidating information on rare diseases, related genes, and patient organisations into a single accessible platform for healthcare professionals, researchers, and patients.
Sources: Orphanet official site
Orphanet has moderate AI-search visibility, scoring 61/100 on Brand Analyzer's AI visibility composite (visibility 75, trust 34, recommendation 67). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Orphanet official site
Orphanet was founded in 1997. Orphanet operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Orphanet provides comprehensive, high-quality information on rare diseases and orphan drugs, including an inventory and encyclopaedia of rare conditions, data on related genes, and a directory of patient advocacy organisations. Its goal is to improve diagnosis, care, and treatment for people affected by rare diseases by consolidating previously fragmented medical knowledge into one trusted, freely accessible resource.
Sources: Orphanet official site
Orphanet scores 67/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Orphanet official site
Orphanet is known for being a leading global reference database for rare disease and orphan drug information. It is recognized for its comprehensive encyclopaedia covering rare diseases, associated genes, and a directory of patient organisations, all offered free of charge to healthcare professionals, researchers, and patients worldwide.
Sources: Orphanet official site
Orphanet can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Orphanet official site
Orphanet is used by healthcare professionals, researchers, and clinicians seeking detailed information on rare diseases and orphan drugs, as well as patients and families affected by rare conditions looking for reliable medical information. Patient advocacy organisations also use Orphanet to access and share information and to connect with the broader rare disease community.
Sources: Orphanet official site
Orphanet is widely used because it consolidates fragmented information on rare diseases and orphan drugs into a single, freely accessible, high-quality resource. Its broad coverage-including disease encyclopaedia entries, gene associations, and a directory of patient organisations-makes it valuable to a diverse audience of clinicians, researchers, and patients seeking reliable, centralized rare disease information.
Sources: Orphanet official site
Orphanet scores 61/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Orphanet has a moderate AI-visibility profile at 61/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (75/100) and its weakest is trust (34/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #25,964 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Orphanet from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Orphanet: Clinisys (76/100), Optum Specialty Pharmacy (76/100), APTA Orthopedics (76/100), Osmo Nutrition (76/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.